CODE v1.0
METADATA
Quick Sheet — What moves the needle
- Target hospital prices paid by private plans. Employers/insurers pay around 254% of Medicare on average; hospital prices are the largest private-sector cost driver. Policy focus: competition, site-neutrality, reference pricing, and ending anti-competitive contract clauses.
- Expand site-neutral payments. Paying the same rate for the same service regardless of setting (especially off-campus HOPDs) yields on the order of $40B–$180B in 10-year federal savings depending on scope; broader national health expenditure savings are plausible.
- Strengthen antitrust & unwind consolidation advantages. Cross-market and within-market hospital mergers raise prices in multiple studies. Enforce the 2023 DOJ/FTC Merger Guidelines; ban anti-steering, MFN, and all-or-nothing clauses.
- Drug prices: build on IRA + PBM reform. Expand Medicare negotiation over time and attack rebate-wall incentives (pass-through pricing, transparency, anti-exclusion rules).
- Fix Medicare Advantage overpayments. Address coding intensity and related factors that add up to tens of billions annually.
- Administrative simplification. U.S. admin costs dwarf peers; prior auth and claims complexity are ripe for standardization and automation (e-PA, APIs, uniform forms, SLAs).
- Be realistic on “care redesign” savings. ACOs/primary-care investments improve quality and equity, but net savings are mixed in large evaluations; don’t over-promise short-run budget gains.
Context: 2023 U.S. health spending was roughly $4.9T (~17.6% of GDP) and was projected to grow ~8% in 2024; bending the price trend matters most.
Header / Context
“Cost” = total national health expenditures (NHE), payer budgets (federal/state/employer), and patient out-of-pocket. The U.S. problem isn’t overuse alone—it’s high unit prices for hospital and drug care plus heavy administrative friction.
C — Clarify
Precise question: Which policies can measurably reduce U.S. health spending growth over the next 3–10 years without unacceptable harms to access or innovation?
Key terms: Site-neutral payment (same pay for same service across settings); HOPD (hospital outpatient department); PBM (pharmacy benefit manager); MA coding intensity (risk-score upcoding vs FFS).
Success metrics (examples): (1) Payer-weighted hospital price index −10–20% vs trend; (2) Federal 10-yr savings ≥$250B cumulative across measures; (3) NHE growth ≤GDP+0 by 2028; (4) No decline in quality/safety metrics.
O — Organize
| Policy lever | How it reduces cost | Evidence & expected magnitude | Risks / counter-arguments | Who acts? |
|---|---|---|---|---|
| Site-neutral payments (start with off-campus HOPDs; consider on-campus expansion) | Eliminates setting-based mark-ups; reduces incentives to acquire physician offices | Independent estimates range from single-digit billions (narrow scope) to about $100B–$180B over 10 years (broader scope). Also lowers beneficiary premiums/copays when applied in Medicare. | Hospital finance stress, esp. rural/safety-net; mitigate with targeted add-ons/transition funds | Congress • CMS |
| Antitrust enforcement + contract reforms | Prevents price-raising consolidation; restores plan steering/tiering | Multiple studies find post-merger hospital price increases (often ~7–10%). Apply 2023 Merger Guidelines; prohibit anti-competitive clauses (anti-steering, MFN, all-or-nothing). | Hospitals cite scale/quality arguments; monitor access & quality indicators | DOJ/FTC • States • Payers |
| Employer & state price tools (reference pricing, centers of excellence, APCDs) | Steers volume to efficient providers; exposes outliers | Large employer datasets show wide price dispersion; employers pay ~254% of Medicare on average—suggests scope for 10–20% price cuts via steering/tiering where quality is maintained. | Member pushback on travel; ensure quality criteria & equity safeguards | Employers • States |
| Medicare Advantage payment integrity | Align MA rates with FFS risk; curb coding intensity & bonus gaming | Independent analysts (e.g., MedPAC) estimate coding-intensity and related overpayments on the order of tens of billions per year; tightening risk models, audits (RADV), and star ratings can yield near-term savings. | Plan exits/benefit cuts; phase-in and protect high-need enrollees | Congress • CMS |
| Drug price actions (IRA expansion + PBM reform) | Negotiate high-spend drugs; break rebate walls; adopt pass-through pricing | Medicare drug negotiation ramps in 2026; PBM practices (spread pricing, formulary exclusions tied to rebates) have been flagged by regulators—supporting pass-through and transparency rules. | Innovation incentives debate; pair with predictable launch pricing & value assessment | Congress • CMS • FTC |
| Administrative simplification (claims/eligibility/PA automation; standards) | Reduce overhead & friction costs for plans and providers | U.S. admin costs far exceed peers (>$1k per capita). New e-prior-auth and data-exchange rules (2026–27) create a floor; states and purchasers can push uniform forms and turnaround-time SLAs. | One-time IT spend; need enforcement teeth & payer/provider accountability | CMS • States • Plans/TPAs • Providers |
| Scope-of-practice & care-team redesign | Increase supply in primary & behavioral care; lower unit cost for routine care | Systematic reviews: expanded NP/PA scope maintains outcomes at lower cost for routine services; helpful for access, modest near-term savings. | Physician opposition; ensure training/oversight and clear boundaries | States • Payers |
| Accountable Care / primary-care investment | Manage total cost of care; prevent avoidable admissions | Large-scale evaluations show mixed net savings; quality and equity often improve. Best results with global budgets/shared savings with downside risk and robust primary-care capacity. | Savings not guaranteed; requires multi-year commitment and aligned benchmarks | CMMI • States • Payers |
| Price transparency enforcement | Enable steering & competitive pressure via usable data | Hospital compliance remains uneven; stronger enforcement and standardized machine-readable data help employers and regulators act on price variation. | Transparency alone rarely cuts prices; must pair with steerage/tiering and purchaser action | CMS • States |
D — Discover
- Hospital prices dominate private-sector spend. Inpatient/outpatient commercial prices average around 2.5× Medicare; target outliers with reference pricing and tiered networks.
- Site-neutrality is a ready-to-go congressional pay-for. Options range from narrow (drug administration only) to broader (most HOPD services). Pair with rural/safety-net cushions.
- Consolidation raises prices without clear quality gains. Use stronger merger scrutiny and police anti-competitive contract terms.
- MA overpayment is meaningful near-term money. Coding-intensity and related factors are sizable; staged corrections produce immediate federal savings.
- PBM rebate dynamics can inflate list prices. Move to pass-through, greater transparency, and anti-exclusion rules; continue FTC enforcement.
- Admin waste is low-politics, high-ROI. Standardize transactions and prior auth; enforce existing rules; align private markets via state law and purchaser coalitions.
- Be sober about delivery-reform savings. Many ACO/PCMH evaluations show quality gains with limited net savings; keep them, but don’t count them as the main pay-for.
E — Evaluate
Verdict (cost-control potential): Strong if we prioritize price-level levers + admin cuts; Moderate if we rely mainly on care-redesign.
Most actionable bundle (3–5 yrs): (1) Site-neutrality (broad off-campus; evaluate on-campus expansion) with rural/safety-net add-ons; (2) MA payment integrity (coding intensity, RADV, star reform); (3) Drug pricing (extend IRA scope & years; PBM pass-through and anti-rebate-wall rules; enforce FTC actions); (4) Antitrust & contracting (merger challenges; ban anti-steering/all-or-nothing clauses); (5) Admin simplification (enforce e-PA & data-exchange deadlines; uniform forms/SLAs; state alignment). Combined, this plausibly delivers federal savings well into the hundreds of billions over 10 years with additional private-sector/NHE reductions, while preserving access and innovation with targeted mitigations.
Guardrails: rural & safety-net stabilization pools; quality floors for steering/tiering; patient out-of-pocket protections during transitions.
Sources (selected)
- CMS National Health Expenditure (NHE) Accounts: historical and projections.
- RAND Hospital Price Transparency studies (employer-paid prices vs Medicare).
- MedPAC: Medicare Advantage coding intensity, RADV, and payment policy analyses.
- KFF: Administrative costs, site-neutral payment explainers, and policy briefs.
- DOJ/FTC (2023) Merger Guidelines and enforcement actions in health care.
- FTC investigations and complaints regarding PBM practices and insulin pricing.
- CMS/IRA materials on Medicare drug price negotiation timelines and scope.
- Peer-reviewed evaluations of ACOs/PCMHs (JAMA, NEJM, CBO summaries).
ATLAS v1.0
METADATA
Quick Sheet — What moves the needle (with TVI)
- Price the same work the same — enact site-neutral payments (start with off-campus HOPDs; evaluate broadened scope) + ban anti-steering/MFN contract clauses.
- Restore competitive pressure — enforce 2023 Merger Guidelines; scrutinize cross-market leverage; empower plan tiering/steerage.
- Pay accurately in MA — correct coding-intensity, tighten RADV/audits, and rationalize Star incentives.
- Rewire drug incentives — extend IRA negotiation over time and curb PBM rebate-wall dynamics (pass-through, transparency, anti-exclusion).
- Cut administrative drag — implement e-prior auth + APIs; standardize forms/SLAs; automate eligibility/claims.
TVI (Transformation Velocity Index) = Sphere Alignment × Change Readiness ÷ Resistance
Working estimate: Alignment 4 × Readiness 3 ÷ Resistance 4 = 3.0 → Medium Velocity. Increase velocity by sequencing low-politics admin wins and pairing price reforms with rural/safety-net cushions.
Five Spheres — Cheatsheet
| Sphere | What matters here | Cost-pressure roots | High-leverage moves |
|---|---|---|---|
| Archetypal (patterns & metaphors) |
Fair prices for equal work; stewardship vs. rent-seeking; “commons” logic for shared infrastructure | Brand power of hospitals/drugs treated as sacred; moral hazard narratives (“don’t ration”) | Reframe to fair dealing (site-neutral = same job, same pay); “pay for value, not venue”; emphasize dignity + duty to patients/taxpayers |
| Technical (systems & metrics) |
Unit prices; market power; coding rules; formulary incentives; admin standards | Commercial hospital prices ≈2.5× Medicare; MA coding intensity; rebate walls; PA/claims friction | Site-neutrality; contract-clause bans; MA payment integrity; PBM pass-through; e-PA/API deadlines; transparency that is actionable |
| Liminal (transition & pacing) |
Short-term disruption risk for rural/safety-net hospitals; plan/network churn; IT lift for standards | Sudden revenue shocks; member abrasion if steerage/tiering is abrupt | Phase-ins, glidepaths, stabilization pools; COE travel benefits; consumer-friendly tiering rollouts; sandbox pilots |
| Axiological (values & ethics) |
Equity (rural/low-income protection); innovation vs. affordability; integrity in contracting/payments | Cross-subsidy opacity; misaligned bonuses; reg capture | Targeted add-ons for high-need providers; predictable launch pricing; conflict-of-interest guardrails; transparent trade-offs |
| Social (stakeholders & power) |
Hospitals, physician groups, PBMs, manufacturers, employers, patients, plans, states, CMS/DOJ/FTC | Consolidation and lobbying; employer fragmentation; consumer inertia | Coalitions of states + jumbo employers; AG/DOJ/FTC actions; beneficiary-visible savings (premiums/copays) to build durable support |
Five Spheres — Diagnostic Table
| Issue | Symptoms | Root Causes | Risks if we act | Mitigations |
|---|---|---|---|---|
| Hospital prices (commercial) | Wide dispersion; average ≈2.5× Medicare for inpatient/outpatient | Market power from consolidation, anti-steering clauses, site-based mark-ups | Revenue stress; service line cuts; political blowback | Stabilization pools for rural/safety-net; phased cuts; quality floors; steerage + COEs |
| Medicare Advantage overpayment | Coding-intensity and bid dynamics inflate federal outlays | Risk-score gaming; bonus inflation; audit lag | Plan exits or benefit trims | Multi-year glidepath; risk model updates; focused RADV; protect high-need groups |
| Drug spending incentives | High list prices; exclusion of lower-list alternatives | Rebate walls via PBM/GPO arrangements; misaligned formulary economics | Manufacturer R&D claims; formulary disruption | Pass-through pricing; transparent value assessment; stepwise negotiation expansion; transition stocks |
| Administrative friction | Prior-auth delays; staff burnout; IT balkanization | Non-uniform standards; weak SLAs; low API adoption | Up-front IT spend; small-practice burden | Pre-cert waivers for high-performers; grants/TA for small practices; strict turnaround times |
| Transparency that doesn’t bite | Data posted, little action | Usability gaps; no steerage/tiering; weak enforcement | Token compliance | State APCDs + employer tools; penalties for non-compliance; tiered networks linked to savings shares |
Sphere Scores & TVI (working)
| Sphere | Alignment (1–5) | Readiness (1–5) | Resistance (1–5) | Notes |
|---|---|---|---|---|
| Archetypal | 4 | 3 | 3 | “Same work, same pay” frames well; avoid “rationing” language |
| Technical | 5 | 3 | 4 | Strong evidence base; requires statutory & rule changes |
| Liminal | 3 | 3 | 4 | Disruption risk concentrated in rural/safety-net + small practices |
| Axiological | 4 | 3 | 3 | Equity & stewardship can anchor coalition |
| Social | 3 | 3 | 5 | Organized incumbents resist; employers & states are fragmented |
TVI = Alignment (4) × Readiness (3) ÷ Resistance (4) = 3.0 → Medium. Raise by: (a) bankable admin wins first, (b) pair price reforms with targeted supports, (c) make savings visible to patients/employers early.
ATLAS Process
SCAN → baseline & evidence
- Spending level: ~$4.9T (2023), ~17.6% of GDP; 2024 growth projected high.
- Private hospital prices average ≈2.5× Medicare; enormous dispersion.
- MA coding-intensity overpayments ≈tens of billions (2025).
- Drug incentives: rebate-driven formularies; FTC action signals structural issues.
- Admin: e-PA and API standards now scheduled with 2026–27 deadlines.
ALIGN → strategy & design
| Objective | Design choice | Guardrails | Owner(s) |
|---|---|---|---|
| Lower unit prices for routine outpatient care | Site-neutral payment (start off-campus HOPDs; consider on-campus phase 2) | Rural/safety-net stabilization pool; phased glidepath; quality floors | Congress • CMS |
| Restore plan leverage | Ban anti-steering/MFN/all-or-nothing clauses; enable tiered networks | Consumer protections; network adequacy; COE travel benefits | States • DOJ/FTC • Payers |
| Reduce MA overpayment | Adjust risk model; strengthen RADV; rationalize Stars | Multi-year phase-in; protect high-need enrollees | CMS • Congress |
| Deflate rebate walls | PBM pass-through pricing; transparency; anti-exclusion rules; expand IRA scope over time | Transition supplies; value-based exceptions; launch-price guardrails | FTC • CMS • Congress |
| Cut admin waste | Implement e-PA + FHIR APIs; uniform forms and SLAs; automate eligibility/claims | Small-practice TA grants; gold-card PA for high-performers | CMS • States • Plans/TPAs • Providers |
TRANSFORM → pilots, sequencing, scale
| Phase (0–36 months) | Action | Milestone | Signal of success |
|---|---|---|---|
| 0–6 mo | Finalize contract-clause bans in targeted states; publish steerage-ready transparency (APCD + employer dashboards) | 3 states live; 50+ employers onboard | 10–15% price reduction on targeted shoppable services for participating plans |
| 6–18 mo | Implement e-PA, begin gold-card pilots; CMS issues site-neutral rulemaking proposal | PA median turnaround ≤48h; denials down 20% | Documented admin cost drop per claim encounter; reduced abandonment |
| 12–24 mo | MA coding-intensity adjustments + RADV ramp; first-wave site-neutral (off-campus) enacted | Federal savings realized in budget score | Beneficiary premiums/copays flatten vs. trend; plan benefits remain stable |
| 24–36 mo | Scale steerage/tiering nationally; evaluate on-campus site-neutral phase 2 | Commercial hospital price index −10–20% vs. baseline in target bundles | NHE growth ≤ GDP+0; quality/safety unchanged or improved |
SUSTAIN → governance & feedback
- Permanent data loop: APCD + CMS + employer consortia publish quarterly price & access scorecards tied to steerage benefits.
- Sunset & review: Five-year review of site-neutral scope; rural add-ons expire unless quality/access criteria justify renewal.
- Incentive hygiene: Public conflict-of-interest disclosures for PBM/GPO and plan-provider contracts; standardized audit trails.
Decision Log & Metrics
| Decision | Rationale | Metric | Target | Owner |
|---|---|---|---|---|
| Adopt site-neutral phase 1 (off-campus) | Largest near-term price lever with manageable risk | Outpatient bundle price index (payer-weighted) | −12% vs. baseline by year 3 | Congress • CMS |
| Ban anti-steering/MFN clauses | Restore competitive contracting & tiering | % lives in tiered networks; observed out-of-network spend | ≥50% lives; −20% OON spend | States • DOJ/FTC • Payers |
| MA payment integrity package | Immediate federal savings without harming access | MA overpayment delta | −$30–40B/yr by year 3 | CMS |
| PBM pass-through & transparency | Deflate rebate walls; align formularies to net value | Share of spend under pass-through; net price/script | ≥70% pass-through; −10% net/script | FTC • States • Plans |
| Admin simplification | Low-politics, system-wide ROI | PA turnaround; claims touch rate; admin $/encounter | ≤48h; −25%; −15% | CMS • Plans • Providers |
Notes
- Balance affordability with access & innovation via targeted cushions and predictable pricing rules.
- Make savings visible to households (premiums/copays) and employers early to build durable coalitions.
- Prefer permanent structural fixes (pricing rules, contract norms, standards) over one-off appropriations.